Participants must be planning to receive ICI-based therapy for a solid tumor malignancy.Patients will have the option of providing blood samples at several time points during the study. Patients complete questionnaires at the start of cancer treatment, weeks 4, 12, 24, and 52. Patients undergo collection of a tissue sample at the start of their routine cancer treatment. To assess the feasibility of using electronic (e)PRO in a multi-center clinical trial setting. To establish a repository of archival tissue and blood/serum specimens for potential predictive and/or prognostic markers of irAE risk. To evaluate the cytokine toxicity (CYTOX) score, a composite measure derived from 11 different cytokine levels, both prior to ICI-based therapy and after 1 cycle of ICI-based therapy as a predictive signature for the development of irAEs.

To track patterns of treatment of irAEs and patterns of toxicity resolution. To measure the burden of chronic, grade 1 and 2 toxicities using methods such as toxicity over time (ToxT). To observe the trajectory of patient-reported adverse events over 12 months using serial assessment with select Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) measures.

To observe the trajectory of patient-reported quality of life and health preferences over 12 months. To prospectively assess the incidence of any grade of non-hematological irAEs and grade 4 hematological irAEs on ICI-based therapy. To both develop and independently validate a risk prediction model for Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher non-hematological immune-related adverse events (irAEs) in the first year of immune checkpoint inhibitor (ICI)-based therapy for the treatment of solid tumors. Why Should I Register and Submit Results?.

Checkit mac